These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2134015)

  • 21. D-peptides as immunogens and diagnostic reagents.
    Van Regenmortel MH; Muller S
    Curr Opin Biotechnol; 1998 Aug; 9(4):377-82. PubMed ID: 9720264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic peptide vaccines.
    Sesardic D
    J Med Microbiol; 1993 Oct; 39(4):241-2. PubMed ID: 7692052
    [No Abstract]   [Full Text] [Related]  

  • 23. Peptides as immunogens: prospects for synthetic vaccines.
    Arnon R
    Curr Top Microbiol Immunol; 1986; 130():1-12. PubMed ID: 2430759
    [No Abstract]   [Full Text] [Related]  

  • 24. Enhancement of the immunogenicity of peptide vaccines.
    Rowlands DJ
    Biochem Soc Trans; 1989 Oct; 17(5):945-7. PubMed ID: 2482816
    [No Abstract]   [Full Text] [Related]  

  • 25. Chemical Platforms for Peptide Vaccine Constructs.
    Ramesh S; Cherkupally P; Govender T; Kruger HG; Albericio F; de la Torre BG
    Adv Protein Chem Struct Biol; 2015; 99():99-130. PubMed ID: 26067818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic peptides as vaccines.
    Rothbard JB
    Biotechnology; 1992; 20():451-65. PubMed ID: 1600388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of synthetic peptides as vaccines for eliciting T-cell immunity.
    Schwartz RH
    Curr Top Microbiol Immunol; 1986; 130():79-85. PubMed ID: 2946557
    [No Abstract]   [Full Text] [Related]  

  • 28. Synthetic T and B cell recognition sites: implications for vaccine development.
    Milich DR
    Adv Immunol; 1989; 45():195-282. PubMed ID: 2665439
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant-independent induction of immune responses by antibody-mediated targeting of protein and peptide antigens.
    Skea DL; Barber BH
    Res Immunol; 1992 Jun; 143(5):568-72. PubMed ID: 1439140
    [No Abstract]   [Full Text] [Related]  

  • 30. Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery.
    Monzavi-Karbassi B; Cunto-Amesty G; Luo P; Kieber-Emmons T
    Trends Biotechnol; 2002 May; 20(5):207-14. PubMed ID: 11943376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic peptide immunogens as vaccines.
    Shinnick TM; Sutcliffe JG; Green N; Lerner RA
    Annu Rev Microbiol; 1983; 37():425-46. PubMed ID: 6357058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proceedings: Specificity and characterization of T cell cooperative factors involved in the response to synthetic poplypeptides.
    Isac R; Mozes E
    Isr J Med Sci; 1975 Dec; 11(12):1385. PubMed ID: 1082880
    [No Abstract]   [Full Text] [Related]  

  • 33. Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity.
    Beekman NJ; Schaaper WM; Tesser GI; Dalsgaard K; Kamstrup S; Langeveld JP; Boshuizen RS; Meloen RH
    J Pept Res; 1997 Nov; 50(5):357-64. PubMed ID: 9401920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular features of class II MHC-restricted T-cell recognition of protein and peptide antigens: the importance of amphipathic structures.
    Berzofsky JA; Cornette J; Margalit H; Berkower I; Cease K; DeLisi C
    Curr Top Microbiol Immunol; 1986; 130():13-24. PubMed ID: 3536326
    [No Abstract]   [Full Text] [Related]  

  • 35. Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age.
    Corradin G; Kajava AV; Verdini A
    Sci Transl Med; 2010 Sep; 2(50):50rv3. PubMed ID: 20861510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of peptides to reconstruct conformational determinants; a brief review.
    Meloen RH; Amerongen AV; Hage-Van Noort M; Langedijk JP; Posthumus WP; Puyk WC; Plasman H; Lenstra JA; Langeveld JP
    Ann Biol Clin (Paris); 1991; 49(4):231-41. PubMed ID: 1928839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automated synthesis and use of N-chloroacetyl-modified peptides for the preparation of synthetic peptide polymers and peptide-protein immunogens.
    Lindner W; Robey FA
    Int J Pept Protein Res; 1987 Dec; 30(6):794-800. PubMed ID: 3440702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic peptides and purified antigens as vaccines.
    Brown F
    Int J Technol Assess Health Care; 1994; 10(1):161-6. PubMed ID: 7512538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular structure and vaccine design.
    Vajda S; Kataoka R; DeLisi C; Margalit H; Berzofsky JA; Cornette JL
    Annu Rev Biophys Biophys Chem; 1990; 19():69-82. PubMed ID: 1694668
    [No Abstract]   [Full Text] [Related]  

  • 40. Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections.
    Hart MK; Palker TJ; Haynes BF
    Pharm Biotechnol; 1995; 6():821-45. PubMed ID: 7551251
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.